Pipeline

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear.

Product Candidate
Investigational Indication
Preclinical Phase 1 Phase 2 Phase 3 Registration
OTIVIDEX
(dexamethasone)

Ménière’s disease

74%

OTIPRIO
(ciprofloxacin otic suspension)
*
Acute otitis media with tubes (AOMT)

57%

OTO-313
(gacyclidine)

Tinnitus

41%

OTO-413
(BDNF)

Hidden hearing Loss

15%

OTO-5XX
(otoprotectant)

Prevent CIHL

15%

OTO-6XX
(hair cell regeneration)

Severe hearing loss

15%

For additional information about Otonomy’s delivery technology, click here.

*The safety and efficacy of OTIPRIO for this use has not been established.